Alexion and Stealth announce agreement for develop and commercialize therapy for PMM
Alexion and Stealth Bio announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) elamipretide is a novel, potential first-in-class therapy. October 10, 2019